Tarsons ProductsNSE:TARSONS +1.36%78 EBITDA Margin % is 33.99% as of Mar. 2026, which is 20% below its 10-year median of 42.72. GuruFocus rates NSE:TARSONS with a GF Score™ of 78/100 and a GF Value™ of ₹564.22 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Tarsons Products ranks better than 92.88% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Tarsons Products's EBITDA for the
three
months ended in Mar. 2026 was ₹411 Mil. Tarsons Products's Revenue for the
three
months ended in Mar. 2026 was ₹1,209 Mil. Therefore, Tarsons Products's EBITDA margin for the quarter that ended in Mar. 2026 was 33.99%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Tarsons Products EBITDA Margin % Related Terms
Tarsons Products EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Tarsons Products's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:TARSONS vs ISRG, BDX, MDLN: EBITDA Margin % Comparison
For the Medical Instruments & Supplies subindustry, Tarsons Products's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tarsons Products EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tarsons Products's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Tarsons Products's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tarsons Products (NSE:TARSONS) has a EBITDA Margin % of 33.99% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tarsons Products and its competitors. This is 20% below median its historical median of 42.72. Over the past decade, Tarsons Products' EBITDA Margin % has ranged from 32.28 to 53.79. According to the industry distribution chart, Tarsons Products ranks #58 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 7.1%.
Is Tarsons Products' EBITDA Margin % too high?
Tarsons Products' current EBITDA Margin % of 33.99% is 20% below median its 10-year median of 42.72. Over the past 10 years, this metric has ranged from a low of 32.28 to a high of 53.79. The Medical Devices & Instruments industry median EBITDA Margin % is 7.47. Tarsons Products' value of 33.99% is 355% above this industry median. Based on the distribution chart, Tarsons Products ranks #58 out of 815 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Tarsons Products has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Tarsons Products' EBITDA Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Tarsons Products ranks #58 out of 815 companies for EBITDA Margin %. This places Tarsons Products in the top 7% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.47. Tarsons Products' value of 33.99% is 355% above this benchmark. Historically, Tarsons Products' own EBITDA Margin % has ranged from 32.28 to 53.79 over the past decade. While the company's 10-year median is 42.72 vs. the industry median of 7.47, Tarsons Products has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.47, based on 815 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tarsons Products's current EBITDA Margin % of 33.99% is 355% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tarsons Products and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tarsons Products's current EBITDA Margin % is 33.99%, which is 20% below median its own 10-year median of 42.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tarsons Products stock overvalued right now?
Based on GuruFocus' analysis, Tarsons Products (NSE:TARSONS) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹564.22, compared to a current price of ₹265.05 — trading 53% below its estimated fair value. The current EBITDA Margin % is 33.99%, which is 20% below median its 10-year median of 42.72 and 355% above the Medical Devices & Instruments industry median of 7.47. Tarsons Products' overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Tarsons Products (NSE:TARSONS), the current EBITDA Margin % is 33.99% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tarsons Products (NSE:TARSONS) Overvalued in 2026?
Based on GuruFocus' analysis, Tarsons Products stock appears to be undervalued.
The current stock price of ₹265.05 is trading 53% below its estimated GF Value™ of ₹564.22.
GuruFocus considers Tarsons Products to be Significantly Undervalued.
Key valuation signals for NSE:TARSONS:
EBITDA Margin %: 33.99% (20% below median its 10-year median of 42.72)
GF Value™: ₹564.22 vs. price of ₹265.05 (53% below fair value)
Industry Position: 355% above the Medical Devices & Instruments median (#58 of 815)
No single metric tells the full story. See the NSE:TARSONS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tarsons Products Ltd is an Indian labware Company engaged in designing, developing, manufacturing, and marketing consumables, reusables, and other including benchtop equipment, used in various laboratories across research organizations, academia institutes, pharmaceutical companies, CROs, diagnostic companies, and hospitals. The Company is also engaged in the manufacturing of a wide range of quality labware products that help scientific discovery and improve healthcare. The company generates the majority of its revenue from the sale of manufactured plastic products. Geographically, the company generates the majority of its revenue from India.
78GF Score
Get the complete analysis for NSE:TARSONS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:TARSONS has been successfully added to your 
